Use of active forms of vitamin D is advocated in patients with chronic kidney disease (CKD) for treatment of mineral bone disease because of the presumption that native forms of vitamin D would not undergo significant activation to calcitriol, the most active biological form of vitamin D. We present secondary analysis looking at bone turnover in subjects who completed the randomized, double blind, placebo-controlled trial investigating the effect of cholecalciferol supplementation on vascular function in nondiabetic CKD stage G3G4 and vitamin D 20 ng/mL (Clinical Trials Registry of India: CTRI/2013/05/003648). Patients were randomized (1:1) to receive either two directly observed oral doses of 300,000 IU of cholecalciferol or matching placebo at baseline and 8 weeks. Of the 120 subjects enrolled, 58 in the cholecalciferol group and 59 in the placebo group completed the study. At 16 weeks, the serum 25(OH)D and 1,25(OH) 2 D levels increased in the cholecalciferol group but not in the placebo group (between-group difference in mean change: 23.40 ng/mL; 95% CI, 19.76 to 27.06; p < 0.001, and 14.98 pg/mL; 95% CI, 4.48 to 27.18; p ¼ 0.007, respectively). Intact parathyroid hormone (iPTH) decreased in the cholecalciferol group (between-group difference in mean change -100.73 pg/mL (95% CI, -150.50 to -50.95; p < 0.001). Serum total and bone-specific alkaline phosphatase (SAP, BAP) and serum C-terminal cross-linked collagen type I telopeptides (CTX-1) were significantly reduced in cholecalciferol group (between group difference for change in mean: -20.25 U/L; 95% CI, -35.14 to -5.38 U/L; p ¼ 0.008 for SAP; -12.54 U/L; 95% CI, -22.09 to -2.98 U/L; p ¼ 0.013 for BAP; and -0.21 ng/mL; 95% CI, -0.38 to -0.05 ng/mL; p ¼ 0.05 for CTX-1). Correlation analysis showed significant correlation of D25(OH)D with DiPTH (r ¼ -0.409, p < 0.0001), D1,25(OH) 2 D (r ¼ 0.305, p ¼ 0.001), DSAP (r ¼ -0.301, p ¼ 0.002), DBAP (r ¼ -0.264, p ¼ 0.004), and DCTX-1 (r ¼ -0.210, p ¼ 0.0230). Cholecalciferol supplementation corrects vitamin D deficiency and is effective in lowering serum intact parathyroid hormone and bone turnover markers in early stages of CKD.
Introduction
M ineral and bone disorders (MBDs) are common, and start early in the course of chronic kidney disease (CKD). (1) Current understanding indicates that vitamin D, calcium, parathyroid hormone (PTH), inorganic phosphate, and fibroblast growth factor 23 (FGF23) are key players in CKD-MBD. (2) Clinical manifestations appear relatively late, but biochemical abnormalities, such as elevations in serum phosphate, FGF23, and PTH levels have been noted in 3%, 50%, and 22% of subjects with estimated glomerular filtration rate (eGFR) 50 to 59 mL/min/1.73m 2 . (3) Abnormality in vitamin D production is central to the genesis of CKD-MBD. Reduced renal 1-a-hydroxylase activity lowers the levels of activated vitamin D3, and causes an increase in PTH secretion. Vitamin D deficiency stimulates the secretion of FGF23 by osteocytes, which further contributes to hyperparathyroidism. (4, 5) The discovery of 1-a-hydroxylase activity in many tissues, including the parathyroid gland, suggests that correction of vitamin D deficiency might ameliorate the secondary hyperparathyroidism of CKD by improving substrate availability, at least in early stages of the disease. Cross-sectional studies have shown an association between circulating vitamin D levels and markers of bone turnover in CKD. (6) However, whether correction of vitamin D deficiency will lead to improvement in CKD-MBD has not been tested in interventional studies.
In a prespecified secondary analysis of a randomized, doubleblind, placebo-controlled trial of cholecalciferol supplementation in nondiabetic vitamin D-deficient subjects with stage G3 to G4 CKD, we investigated the effect of oral cholecalciferol supplementation on markers of mineral metabolism, which included 1,25(OH) 2 D, FGF23, PTH, serum C-terminal cross-linked collagen type I telopeptides (CTX-1), total and bone-specific alkaline phosphatase (SAP, BAP).
Subjects and Methods

Study subjects and biomarker evaluation
This single-centre, parallel arm, randomized, double-blind, placebo-controlled trial was done at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The study was approved by Institute Ethics Committee, registered at Clinical Trials Registry of India (CTRI/2013/05/ 003648) and all subjects provided written informed consent. The detailed study protocol and subject enrolment process has been described. (7) Briefly, 120 stable nondiabetic, CKD stage G3-G4 subjects of either sex between the ages of 18 and 70 years with serum 25(OH)D levels 20 ng/mL were randomized in a 1:1 allocation ratio to receive two directly supervised doses of either 300,000 IU of cholecalciferol or matching placebo at baseline and 8 weeks later. Randomization was done by computergenerated Bernoulli random number table, and the investigators as well as the patients were blinded.
Serum creatinine, calcium, inorganic phosphorus, lipid profile, uric acid, and hemoglobin were measured at baseline and 16week visits on fasting blood samples. Serum 25(OH)D was measured by enzyme immunoassay (EIA) [Immunodiagnostic Systems (IDS), Boldon, UK], certified for calculation of 25(OH)D by the Center for Disease Control and Prevention (CDC) Vitamin D Standardization Certification Program (VDSCP). (8, 9) 
Outcomes
We investigated changes in serum levels of 1,25(OH) 2 D, intact-PTH, intact-FGF23, inorganic phosphorus, calcium, SAP, BAP, and CTX-1.
Statistical analysis
Data are presented as mean AE SD, mean (95% CI), and median (interquartile range) as appropriate. Continuous variables were compared with independent samples Student's t test if normally distributed, or with Mann-Whitney U test if the distribution was skewed. Categorical variables were analyzed by chi square test or Fisher's exact test as appropriate. Paired Student's t test and Wilcoxon signed-rank test were used for within-group comparisons. Correlation analysis was performed using Spearman's rank correlation. Subgroup analysis based on gender, baseline vitamin D tertiles, and age ( 50 years and >50 years) was performed to see any effect on change in iPTH within subgroups. Interaction between intervention and subgroup variables was examined using general linear model. Two tailed p values <0.05 were considered statistically significant. Analyses were conducted using the Statistical Package for the Social Sciences (SPSS) software for Macintosh, version 21.0 (IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics of the study subjects are shown in Table 1 . The demographic details, causes of CKD, and use of medications were similar in both groups. Biochemical parameters and circulating biomarker levels did not differ between the groups at baseline ( Table 2 ).
Change in biochemical parameters and circulating biomarkers
At 16 weeks, the serum 25(OH)D levels increased in the cholecalciferol group (mean change: þ24.91 ng/mL; 95% CI, 21.77 to 28.06 ng/mL; p < 0.001; Table 3 ) but not in the placebo group (þ1.51 ng/mL; 95% CI, -0.46 to 3.48 ng/mL; p ¼ 0.13; Table 3 ). The difference in change in 25(OH)D levels between the two groups was significant (p < 0.001; Tables 3 and 4 ). Similarly, serum 1,25(OH) 2 D levels increased in the cholecalciferol (15.46 pg/mL; 95% CI, 5.42 to 25.50 pg/mL; p ¼ 0.003) but not in the placebo group (0.48 pg/mL; 95% CI, -4.65 to 5.62 pg/mL; p ¼ 0.85), with significant difference between the groups for change over 16 weeks (p ¼ 0.007).
Serum levels of iPTH showed a significant decline in the cholecalciferol group at 16 weeks whereas in placebo group there was a rise. This was accompanied by a significant decrease in total SAP, BAP, and CTX-1 levels in cholecalciferol group, whereas the levels remained unchanged in the placebo-treated subjects. The between group difference in change was significant for all these markers (Tables 3 and 4 ).
Though serum level of iFGF23 did show a decreasing trend in the cholecalciferol group, it did not reach statistical significance. Change in iFGF23 in the placebo group, and between-group difference for change in iFGF23 were not significant. A numeric increase was noted in serum calcium in the cholecalciferol group, whereas it decreased significantly in the placebo group, leading to a significant between-group difference in mean change. Serum uric acid decreased in the cholecalciferol-treated subjects but not in the placebo group. Serum inorganic phosphorus (Pi), serum creatinine, eGFR, and hemoglobin levels did not change significantly in either group (Tables 3 and 4 ).
Correlation analysis for biomarkers of mineral metabolism
We examined the correlation of change (D) in 25(OH)D levels at baseline and at 16 weeks with that in the other markers, and found a significant correlation of
In subgroup analyses, the change in iPTH remained significant in males, lower tertiles (tertile 1 and 2) of baseline vitamin D levels, and groups based on age ( 50 years and >50 years) with no significant heterogeneity of treatment effect on DiPTH across these subgroups (Table 5 ).
Discussion
This study provides strong evidence that correction of native vitamin D deficiency with cholecalciferol supplementation efficiently achieves sufficient level of 25(OH)D in predialysis CKD subjects and has a favorable effect on several biochemical parameters of CKD-MBD, including suppression of secondary hyperparathyroidism, change in bone turnover markers, and favorable trend in FGF-23 levels. Change in serum 25(OH)D level significantly correlated with the change in markers of mineral metabolism, indicating that vitamin D deficiency is a potentially modifiable risk factor for bone mineral disease in subjects with stage G3-G4 CKD.
Vitamin D deficiency has been shown to be associated with hyperparathyroidism and increased bone turnover in subjects with CKD, as shown by elevation in CTX-1 and BAP. (6) An association of SAP with vitamin D deficiency has been documented in various settings. (10) (11) (12) McKenna and colleagues (13) reported a high level of SAP in vitamin D-deficient elderly individuals and decline with seasonal rise in vitamin D level. Other observational studies and randomized trials have investigated the effect of vitamin D supplementation in healthy adults and children. Most showed a significant decline in PTH, but the effect on bone formation and resorption markers was inconsistent. (14) (15) (16) (17) (18) (19) Chandra and colleagues (20) randomized 34 subjects with stage G3-G4 CKD and 25(OH)D level <30 ng/mL to There was a decrease in the week 12 iPTH levels, but there was no difference in the levels of bone turnover markers. Despite the efficacy of cholecalciferol supplementation in reducing iPTH levels in subjects with predialysis CKD, (21, 22) recent studies have focused on activated vitamin D analogues. (23) The findings of the present study show that a sufficient level of circulating 25(OH)D in subjects with CKD is important to restrict PTH secretion/synthesis and reduce bone turnover, and could be particularly relevant in areas with widespread vitamin D deficiency as a cheap alternative.
PTH suppression can be mediated by several mechanisms. 25 (OH)D is a substrate for renal 1-a-hydroxylase, which produces 1,25(OH) 2 D from circulating 25(OH)D, which binds to the vitamin D receptor on parathyroid cells, to suppress the secretion of PTH. (24) This was supported by the finding that vitamin D supplementation led to an increase in levels of circulating 1,25 (OH) 2 D 3 . Parathyroid gland cells have also been shown to express 1-a-hydroxylase, which can suppress PTH by local production of 1,25(OH) 2 D 3 . Finally, an increase in calcium level can suppress the PTH secretion, but whether the level can go down to normal remains a matter of investigation. Though between-group difference in serum uric acid levels was not significant, decrease in serum uric acid levels was noted in the cholecalciferol group. PTH might modulate serum uric acid levels, as suggested in a recent report where elevated PTH was shown to impair uric acid excretion from kidneys and gut in CKD animals. (25) Increased FGF23 can inhibit the PTH expression, mediated by Klotho-FGFR1c activity in CKD subjects. (4) Elevated FGF23 levels are also associated with decrease in 1,25(OH) 2 D because of their suppressive effect on 1-a-hydroxylase. (22) In this context, the declining trend in FGF23 with vitamin D supplementation, and the positive correlation of change in FGF23 with change in iPTH are of interest. Some studies have reported a rise in FGF23 level after supplementation of cholecalciferol (22) and paricalcitol. (23) In our study, a fall in PTH levels and elevated 1,25(OH)D would have had competing effects on FGF23. (26) The interaction of FGF23 with iPTH, 1,25(OH) 2 D, and 25(OH)D is complicated and needs further investigation.
Vitamin D deficiency is almost universal in the CKD population. The recently updated Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Guidelines (27) make an 2C recommendation to correct vitamin D deficiency in CKD subjects. Also, the exact protocol for correction is not welldefined. We used two doses of 300,000 IU, 8 weeks apart, which effectively replenished the 25(OH)D levels accompanied by increase in active vitamin D and reduction in iPTH level and markers of bone turnover and no events of significant hypercalcemia and hyperphosphatemia. However, this strategy needs to be monitored for its long-term impact.
There are some limitations of our study which include the single-center design, exclusion of diabetic subjects, absence of bone biopsy, lack of assessment of dietary intake and urinary excretion of calcium and phosphate, and a short duration of intervention and follow-up. The strength of this study is that it was a randomized, double-blind, placebo-controlled study with adequate sample size.
In conclusion, correction of vitamin D deficiency with cholecalciferol supplementation suppressed secondary hyperparathyroidism and favorably changed biochemical markers of mineral metabolism in subjects with stage G3-G4 CKD.
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